To study the molecular mechanism of the differentiation target genes. [8][9][10][11] Furthermore, all-trans RA restores the 
Introduction of all-trans RA brings high rates of complete Materials and methods remission and longer survival. [2] [3] [4] Clinical effectiveness is mostly determined by the presence of t(15;17), which is a Cell culture and agents reciprocal rearrangement between the PML gene and the retinoic acid receptor alpha (RAR␣) gene. 5, 6 The PML-RAR␣ The APL cell line, NB4, 24 was obtained from Dr M Lanotte fusion protein generated by the translocation is not only asso-(Hôpital Saint-Louis, Paris, France) and cultured in RPMI 1640 ciated with leukemogenesis but also with responsiveness to supplemented with L-glutamine (2 mM), antibiotics and 10% all-trans RA.
7-13 These two paradoxical characteristics can be fetal calf serum at 37°C in a humidified CO 2 incubator. Culexplained by the structure of PML-RAR␣; that is, PML-RAR␣ tures were initiated by seeding 2 × 10 5 cells/ml of fresh retains the dimerization property with PML or the retinoid X medium and maintained at 2-5 × 10 5 cells/ml by adjusting receptor (RXR). Thus, the functions of PML and/or RXR are cell concentrations by adding fresh culture medium with supsequestrated by PML-RAR␣ in a dominant negative manner, plements when necessary. To obtain RA-resistant NB4 cells, which would be associated with the differentiation block at NB4 was cultured in the presence of 1 nM all-trans RA, and the promyelocytic stage.
7,11 PML-RAR␣ also retains a ligandthis concentration was gradually increased. receptor domain for RA, and the function of PML-RAR␣ has All-trans RA, 9-cis RA and 13-cis RA were purchased from been thought to be modulated by binding RA. Under a pharSigma Chemical (St Louis, MO, USA) and Am80 25 was a genmacological concentration of all-trans RA, the in vitro transerous gift from Dr K Shudo (Tokyo University, Tokyo, Japan). fected PML-RAR␣ gene overstimulates the expression of RAR␣ They were dissolved in ethanol to a concentration of 1 mM, and stored at −20°C. 8-(4-chlorophenylthio) adenosine cyclic 3Ј,5Ј-monophosphate (8-CPT-cAMP, a cAMP analog), isbutyl-(INF) ␥ was provided by the Otsuka Pharmaceutical Company incubated for 1 h at room temperature. The immunofluorescence was detected using a fluoromicroscope (BH-2; (Tokyo, Japan).
Olympus, Tokyo, Japan).
Analysis for differentiation
NB4 and NB4/RA cells were cultured with the indicated additives and cellular differentiation was analyzed. Cell numbers Southern and Northern analyses and viability were assessed by the trypan blue dye exclusion test. Myeloid differentiation was evaluated on day 3 and day 5 by the morphology of the cells, nitroblue tetrazolium (NBT) Southern blot and Northern blot analyses of the RAR␣ gene have been described previously. 19, 27 A partial cDNA correreduction activity, and the expression of cell surface markers. For morphological observation, cells were prepared on slides sponding to exons 2, 3 and 4 was subcloned from a full-sized cDNA clone 28 provided by Prof Pierre Chambon (INSERM, by cytospin, and stained with a May-Giemsa solution. For the NBT assay, cells were mixed with a solution containing 12-Strasbourg, France) and used as a probe for the RAR␣ gene. O-tetradecanoyl phorbol 13-acetate (TPA) (Sigma) and NBT (Sigma) as described, 26 and percentage of positive cells was evaluated by counting 500 cells. The following cell surface markers were analyzed by flow cytometry (FACScan; Becton Dickinson, San Jose, CA, USA): CD11a, CD11b, CD11c, Cloning and sequencing CD13, CD14, CD15, CD18, CD33, CD38 and CD71.
Total cellular RNA was prepared from NB4/RA and NB4 cells using the guanidium isothiocyanate/cesium chloride method.
Immunoblotting
Complementary DNA (cDNA) was synthesized from 10 g of total RNA using random hexamer primers (Gibco BRL, GaiThe preparation of an antiserum against PML has been reported previously. 19 Crude nuclear extracts were prepared thersburg, MD, USA) and Moloney murine leukemia virus reverse transcriptase (SuperScript II; Gibco BRL), according to from NB4 cells. The cells were washed with cold phosphatebuffered saline (PBS), and resuspended in buffer A (10 mM the manufacturer's recommendations. The PML-RAR␣ transcript was amplified by nested polymerase chain reaction Hepes pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM dithiothreitol (DTT)) for 10 min at 4°C. After centrifugation for 1 min at (PCR). The first PCR amplification reaction contained 2 l from a total of 20 l cDNA, 50 pmol of each sense (5Ј-AAG-2000 g, the cells were lysed in buffer A containing 0.2% NP-40, 1 g/ml leupeptin, 10 mM ethylene glycol-bis(␤-amino-GAGGCAAGGTTGGCTCGGAGCT-3Ј) and anti-sense (5Ј-CTGAGGCTGGGGCTACAGCTGCCT-3Ј) primer correspondethyl ether)-N,N,NЈ,NЈ-tetraacetic acid (EGTA) and 0.2 mM phenylmethylsulfonyl fluoride (PMSF; Sigma). The nuclei were ing to PML exon 6 and RAR␣ exon 4, respectively, 0.2 mM of each deoxynucleotide triphosphate, 10 mM Tris-HCl pH 8.3, pelleted by centrifugation for 1 min at 2000 g and nuclear proteins were extracted in buffer B (20 mM Hepes pH 7.9, 0.2 mM 50 mM KCl, 1.5 mM MgCl 2 , 0.001% gelatin (w/v) and 2.5 U Taq polymerase (Amplitaq; Perkin Elmer, Norwalk, CT, USA). EDTA, 0.5 mM DTT, 0.42 M NaCl, 25% (v/v) glycerol, 1 g/ml leupeptin, 10 mM EGTA and 0.2 mM PMSF) for 20 min on ice.
Denaturing, annealing, and extension steps were performed at 94°C for 30 s, 68°C for 90 s, and 72°C for 2 min, respectAfter centrifugation for 3 min at 15 000 g, the supernatant was used as nuclear extracts.
ively, for 40 cycles on a GeneAmp PCR system 2400 (Perkin Elmer) including an initial 3-min denaturation step at 94°C The nuclear extracts were separated by 8% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and electroblotted onto and a final extension step at 72°C for 10 min. The second round PCR was performed using 2 l of the first round mixture Immobilon PVDF (Millipore, Bedford, MA, USA). The membranes were blocked in PBS with 3% non-fat dry milk, then with each respective inner primer, 5Ј-AGGTCTTCCTGCCCAAC AGCAACCA-3Ј for the sense and incubated with the rabbit anti-PML antibody (2 g/ml) for 2 h at room temperature. Then they were washed with PBS con-5Ј-CCCGGC-TGTCCGCCAGAGTGTCCA-3Ј for the antisense, under the same conditions used in the first round. The taining 0.5% Tween 20, and incubated with peroxidase-conjugated goat anti-rabbit IgG (Bio-Rad, Richmond, CA, USA) amplified product was cut out from an agarose gel, purified with a Qiaex gel extraction kit (Qiagen, Chatsworth, CA, diluted at 1:2000 for 2 h at room temperature. After washing, they were stained with a Konica-Immunostaining kit (Konica, USA), and cloned into the pMOSBlue T-vector (Amersham, Buckinghamshire, UK) according to the manufacturer's recTokyo, Japan).
ommendation. These procedures were repeated, and a total of 20 recombinant clones were obtained from two experiments. Plasmid DNA was prepared using a Qiaprep plasmid extracImmunostaining tion kit (Qiagen), and both strands were sequenced using fluorescein-conjugated-21M13 and T7 primers in a DNA Cells suspended in RPMI 1640 containing 10% fetal calf serum were prepared on histological slides. Specimens were sequencer (373-A; Applied Biosystems, Foster City, CA, USA). The RAR␣ transcript was also amplified by nested PCR using completely dried and fixed with periodate-lysine-paraformaldehyde (0.01 M NaIO 4 , 0.075 M phosphate buffer, 2% paraforthe same antisense primers for the rearranged RAR␣ gene and sense primers corresponding to RAR␣ exon 2, 5Ј-TCTmaldehyde, pH 6.2) for 20 min at 4°C. The slides were washed with PBS and incubated with anti-PML antibody GACCACTCTCCAGCACCAGCTT-3Ј for the first round and 5Ј-CAGTTAGTGGATATAGCACACCATC-3Ј for the second, (5 g/ml) for 1 h at room temperature. After washing with PBS, 1:100 diluted fluorescence-labeled goat anti-rabbit IgG under the same conditions described above. The amplified product was cloned and sequenced as described above. (Cappel, West Chester, PA, USA) was added to the slide and Results inhibitor), interferon ␥, or clotrimazole (p450-inhibitor). However, although 8-CPT-cAMP alone showed no effect, the combination of all-trans RA with 8-CPT-cAMP induced differenGeneration of a RA-resistant NB4, NB4/RA tiation: morphological changes, induction of CD11b and NBT reduction activity, and down-regulation of CD71 (Tables 1  NB4 cells were cultured in gradually increasing concentrations of all-trans RA. After 12 months of culture, RA-resistand 2). Nevertheless, the positive rates of the NBT reduction assay, and expression of CD11b and CD18 were lower than ant NB4 cells were obtained, and a subline of NB4, designated NB4/RA, was established after two-times limiting those of the original NB4 cells treated with all-trans RA alone. dilutions. NB4/RA cells had almost the same proliferation rate as the original line, and showed resistance to 1 M all-trans Detection of PML and PML-RAR␣ using RA: no differentiation and no growth suppression. The resistimmunostaining and immunoblot analysis ance to all-trans RA was stable and persisted even after the elimination of all-trans RA from the culture medium. NB4/RA A microgranular pattern of PML immunostaining is distinccells showed the same morphological features as NB4 cells, tively observed in APL, while a nuclear large speckled pattern but expressed lower levels of CD11a and CD18, and a higher level of CD38 than NB4 cells (Table 1) . Table 2 NBT reduction activity of NB4 and NB4/RA Treatment NB4 NB4/RA
Induction of differentiation
The parental NB4 cells were induced to differentiate by 1 M all-trans RA, which was characterized by the indented shape CD11c, CD18 and NBT reduction activity (Tables 1 and 2 ). RA (Table 1) .
In contrast, NB4/RA cells were not morphologically more, CD11b and NBT reduction activity were not induced, any isoforms of RAs (all-trans, 9-cis and 13-cis), or by a com-
bination of all-trans and 9-cis RAs ( Table 2 ).
All-trans RA + CTM 17 67 1 2
NB4/RA cells were not differentiated by a synthetic retinoid, Am80, which has a higher differentiation-inducing activity nations of all-trans RA with IBMX (phosphodiesterase-
Figure 1
Immunostaining of NB4 and NB4/RA cells using anti-PML antibody. Immunostaining of NB4 cells using anti-PML antibody showed a microgranular pattern, which was restored to a discrete speckled pattern by the treatment with 1 M all-trans RA (ATRA). In NB4/RA cells, the similar immunostaining pattern was observed but was not significantly changed even by the treatment with ATRA and 8-CPT-cAMP.
is common in other types of leukemia and normal hematopoassociated with subsequent changes of the PML immunostaining pattern. Furthermore, there might be another pathietic cells.
14,15 Using immunofluorescence, we studied the intracellular localization of PML and PML-RAR␣ in NB4 and way inducing differentiation which does not require the down-regulation of PML-RAR␣ and the restoration of PML NB4/RA cells (Figure 1 ). Both cell lines showed microgranular patterns in the nuclei and cytoplasm. In NB4 cells, these fealocalization. tures were changed by 1 M all-trans RA after 24 h; the number of small granules was decreased, the size of granules was increased, and the cytoplasmic staining was reduced. HowMolecular studies of the RAR␣ and PML-RAR␣ genes ever, the PML staining pattern was not changed in NB4/RA and transcripts cells treated either with all-trans RA alone or with a combination of all-trans RA and 8-CPT-cAMP. After 5 days treatment
Since treatment with all all-trans RA did not significantly affect with the combination, the intensity of PML immunostaining the PML immunostaining pattern and the amount of PMLwas slightly decreased (Figure 1) . RAR␣ in NB4/RA, we supposed that molecular alternation Next, we serially studied the amounts of PML-RAR␣ in NB4 most probably resided in PML-RAR␣ itself. Thus, the PMLand NB4/RA cells treated with RA by immunoblot analysis. As RAR␣ chimeric gene was studied by Southern and Northern shown in Figure 2 , the amounts of PML-RAR␣ were markedly blot analyses. Southern blot analysis revealed that both cell decreased in NB4 cells treated with all-trans RA. In NB4/RA lines had the same rearranged pattern of the RAR␣ gene as cells, however, PML-RAR␣ was not diminished even by the well as the germ line bands (Figure 3a) . Northern blot analysis combination of all-trans RA and 8-CPT-cAMP (Figure 2) .
showed similar amounts of PML-RAR␣ fused transcripts and These data suggest that the down-regulation of PML-RAR␣ is RAR␣ transcripts (Figure 3b ). Then we cloned and sequenced the PML-RAR␣ transcripts from NB4 and NB4/RA cells. In all recombinant clones from NB4/RA cells, we found a C to T substitution at nucleotide 2608 in the PML-RAR␣ transcript (Type L), which changes Pro (CCG) to Leu (CTG) at codon 900 (Figure 4 ). This replacement was homogeneous, because oligonucleotide probe corresponding to normal sequence did not hybridize with the PML-RAR␣ fragment amplified from NB4/RA cells (data not shown). On the other hand, no molecular alteration was found in the RAR␣ transcripts from NB4/RA cells.
Figure 2
Immunoblot analysis using anti-PML antibody. The nuclear extracts from NB4 and NB4/RA cells treated with the reagents were analyzed with the anti-PML antibody. The PML-RAR␣ band NB4 and found a missense mutation at codon 900 of PML-
Figure 3
Southern and Northern blot analyses using the RAR␣ gene probe corresponding to exons 2, 3 and 4. (a) Southern blots of the RAR␣ gene after digestion with EcoRI (E), BamHI (B), HindIII (H). Both NB4 and NB4/RA cell lines had the same rearrangements in addition to the germ line RAR␣ gene. Placental DNA was used as the germ line control. (b) Northern blots of the PML-RAR␣ and RAR␣ transcripts. Both cells showed apparently identical amounts of PML-RAR␣ (4.6 kb) and RAR␣ transcripts (3.8 and 2.8 kb). The applied mRNA was confirmed using a cDNA for glycerol-3-phosphate dehydrogenase (G3PDH) as a probe.
Figure 4
Sequence analysis of the PML-RAR␣ transcript. The PML-RAR␣ transcript was amplified using nested PCR as described in Materials and methods. A single base substitution, C to T, was found in the PML-RAR␣ transcript (Type L) from NB4/RA cells, which changes Pro (CCG) to Leu (CTG) at codon 900 in the AF-2 domain of PML-RAR␣. Data on reverse strand are presented.
RAR␣. This position corresponds to codon 407 of RAR␣, and 410, significantly decreased the RA binding activity and increased the dissociation constants for RAs. 33 Accordingly, which is located within the AF-2 activation domain (AD). There have been several reports on the relationship between the mutation of PML-RAR␣ might significantly affect the RA binding characteristics. Furthermore, since the mutation from RA resistance and mutation of RAR␣. Pratt et al 29 first reported a RA-resistant mouse embyronal carcinoma cell line with a Pro to Leu is accompanied by hydrophobic change, it might also affect AF-2 activity which is coded by the C-terminal portermination codon at 391, which was a dominant negative mutation. Robertson et al, 30 Li et al 31 and Kizaki et al 32 tion adjacent to the mutated locus. The biochemical significance of this mutation on RA binding and trans-activation reported the same mutation in RA-resistant HL60 cells: from Gln (CAG) to Stop (TAG) at codon 411. The amino acid needs to be elucidated in the future. Most importantly, the degradation of the mutated PMLsequence from codon 406 to 419 in the AF-2 AD, which sequence is MPPLI . EMLE, is conserved in RAR␣, RAR␤ and RAR␣ was not accelerated by exposure to RA. The mutated PML-RAR␣ bound with RA may be hardly recognized by the RAR␥. This region potentially forms ␣-helix and is the most critical domain for RA binding and trans-activation. 28 Partidegradation pathway, 19 or the mutant may have low RA-binding activity as described above. Since the decrease of PMLcularly, the site-specific mutagenesis experiment showed that amino acid alternations of M, P and E, at codon 406, 407
RAR␣ relieves the dominant negative block of differen- also established another subline, R2, which apparently lacked one by one using an in vitro transfection assay.
14: 1471-1479.
In summary, differentiation of APL by RA is triggered 
